HUMAN DISEASE MODELED by tp53^zdf1/zdf1; nn1004Tg

Human Disease	Conditions	Citations
hepatocellular carcinoma	control	Lin et al., 2019

GENE EXPRESSION
Gene expression in tp53^zdf1/zdf1; nn1004Tg

PHENOTYPE
Phenotype in tp53^zdf1/zdf1; nn1004Tg

Phenotype	Conditions	Figures
hepatocyte fatty, abnormal	standard conditions	Fig. 6  from Lu et al., 2013
hepatocyte hyperplastic, abnormal	standard conditions	Fig. 6 ,  Fig. 7  from Lu et al., 2013
hepatocyte mitotic cell cycle increased frequency, abnormal	standard conditions	Fig. 6 ,  Fig. 7 ,  Fig. 8  from Lu et al., 2013
hepatocyte nucleolus prominent, abnormal	standard conditions	Fig. 6 ,  Fig. 7 ,  Fig. 8  from Lu et al., 2013
hepatocyte nucleus increased size, abnormal	standard conditions	Fig. 6 ,  Fig. 7 ,  Fig. 8  from Lu et al., 2013
liver cdk2 expression amount, ameliorated	chemical treatment by injection: sorafenib	Fig. 5  from Lin et al., 2019
liver cdk1 expression amount, ameliorated	chemical treatment by injection: sorafenib	Fig. 5  from Lin et al., 2019
liver cdk1 expression amount, ameliorated	chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	Fig. 5  from Lin et al., 2019
liver ccne1 expression amount, ameliorated	chemical treatment by injection: sorafenib	Fig. 5  from Lin et al., 2019
liver ccne1 expression amount, ameliorated	chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	Fig. 5  from Lin et al., 2019
liver cdk2 expression amount, ameliorated	chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	Fig. 5  from Lin et al., 2019
liver dysplastic, abnormal	control	Fig. 5  from Lin et al., 2019
liver hyperplastic, abnormal	control	Fig. 5  from Lin et al., 2019
liver ccne1 expression increased amount, abnormal	control	Fig. 5  from Lin et al., 2019
liver cdk2 expression increased amount, abnormal	control	Fig. 5  from Lin et al., 2019
liver cdk1 expression increased amount, abnormal	control	Fig. 5  from Lin et al., 2019
liver structure, ameliorated	chemical treatment by injection: sorafenib	Fig. 5  from Lin et al., 2019
liver structure, ameliorated	chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	Fig. 5  from Lin et al., 2019
liver hepatic tumor increased occurrence, abnormal	standard conditions	Fig. 6 ,  Fig. 7 ,  Fig. 8  from Lu et al., 2013
liver hepatocellular carcinoma amount, ameliorated	chemical treatment by injection: sorafenib	Fig. 5  from Lin et al., 2019
liver hepatocellular carcinoma amount, ameliorated	chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	Fig. 5  from Lin et al., 2019
liver hepatocellular carcinoma increased amount, abnormal	control	Fig. 5  from Lin et al., 2019
liver lipid amount, ameliorated	chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	Fig. 5  from Lin et al., 2019
liver lipid amount, ameliorated	chemical treatment by injection: sorafenib	Fig. 5  from Lin et al., 2019
liver lipid increased amount, abnormal	control	Fig. 5  from Lin et al., 2019
liver spindle cell sarcoma increased occurrence, abnormal	standard conditions	Fig. 7 ,  Fig. 8  from Lu et al., 2013